Immutep reaches enrollment target for INSIGHT-003 trial

Immutep announces the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating Immutep’s lead product candidate, eftilagimod alpha as part of a triple combination therapy with standard-of-care anti-PD-1 therapy and chemotherapy. In a poster presented at the Society for Immunotherapy of Cancer Annual Meeting 2022, initial results in 1L NSCLC patients show the triple combination therapy is well-tolerated and provides promising early signals of therapeutic activity with an Objective Response Rate of 72.7% and a Disease Control Rate of 90.9% . Nine patients had a PD-L1 Tumour Proportion Score of less than50% and this group reported an encouraging ORR of 66.7% and DCR of 88.9%. Patients with a PD-L1 of less than50% represent approximately two-thirds of the 1L NSCLC patient population and are less responsive to anti-PD-1 therapy compared to patients with a PD-L1 TPS of greater than or equal to50%. Additional data from INSIGHT-003 is expected to be presented throughout calendar year 2023. For more information on the study, please see the poster titled ‘Feasibility of eftilagimod alpha combined with standard-of-care-therapy in advanced non-small-cell lung cancer.